Subclinical atherosclerosis as a target of therapy: Potential role of statins

American Journal of Cardiology

Volumn 93, Issue 6, 2004, Pages 737-740

  Kastelein, John J P ^a,b   Stroes, Erik S G ^a   De Groot, Eric ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CARRIER PROTEIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; PRAVASTATIN; PROTEIN INHIBITOR; RESIN; SIMVASTATIN; STATIN;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 1542722290     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.11.072     Document Type: Note

References (37)

1. Napoli C., Glass C.K., Witztum J.L., Deutsch R., D'Armiento F.P., Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood Fate of Early Lesions in Children (FELIC) study. Lancet. 354:1999;1223-1241.
2. Berenson G.S., Bogalusa Heart Study Research Group. Childhood risk factors predict adult risk associated with subclinical cardiovascular disease the Bogalusa Heart Study. Am J Cardiol. 90:(suppl):2002;3L-7L.
3. Cuomo S., Guarini P., Gaeta G., De Michele M., Boeri F., Dorn J., Bond M.G., Trevisan M. Increased carotid intima-media thickness in children-adolescents, and young adults with a parental history of premature myocardial infarction. Eur Heart J. 23:2002;1345-1350.
4. Jaffer F.A., O'Donnell C.J., Larson M.G., Chan S.K., Kissinger K.V., Kupka M.J., Salton C., Botnar R.M., Levy D., Manning W.J. Age and sex distribution of subclinical aortic atherosclerosis a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 22:2002;849-854.
5. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 342:2000;145-153.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals a randomised placebo-controlled trial. Lancet. 360:2002;7-22.
7. ASCOT Investigators, Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) a multicentre randomised controlled trial. Lancet. 361:2003;1149-1158.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
9. Assmann G., Cullen P., Schulte H. Simple scoring system for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) Study. Circulation. 105:2002;310-315.
10. Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, Sijbrands EJG, Kastelein JJP. Arterial intima-media thickness in childhood. A study in familial hypercholesterolemia heteroygotes and their siblings. Lancet 2004;363:369-380.
11. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Bonadonna R.C., Muggeo M. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome prospective data from the Bruneck Study. Diabetes Care. 26:2003;1251-1257.
12. Pannacciulli N., De Pergola G., Ciccone M., Rizzon P., Giorgino F., Giorgino R. Effect of family history of type 2 diabetes on the intima-media thickness of the common carotid artery in normal-weight, overweight, and obese glucose-tolerant young adults. Diabetes Care. 26:2003;1230-1234.
13. Grundy S.M. Age as a risk factor you are as old as your arteries. Am J Cardiol. 83:1999;1455-1457.
14. McGill H.C. Jr, McMahan C.A., Zieske A.W., Sloop G.D., Walcott J.V., Troxclair D.A., Malcom G.T., Tracy R.E., Oalmann M.C., Strong J.P., Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. Arterioscler Thromb Vasc Biol. 20:2000;1998-2004.
15. Grobbee D.E., Bots M.L. Statin treatment and progression of atherosclerotic plaque burden. Drugs. 63:2003;893-911.
16. Fayad Z.A., Fuster V. The human high-risk plaque and its detection by magnetic resonance imaging. Am J Cardiol. 88:(suppl):2001;42E-45E.
17. Corti R., Fayad Z.A., Fuster V., Worthley S.G., Helft G., Chesebro J., Mercuri M., Badimon J.J. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation. 104:2001;249-252.
18. Hoff J.A., Daviglus M.L., Chomka E.V., Krainik A.J., Sevrukov A., Kondos G.T. Conventional coronary artery disease risk factors and coronary artery calcium detected by electron beam tomography in 30, 908 healthy individuals. Ann Epidemiol. 13:2003;163-169.
19. Arad Y., Spadaro L.A., Goodman K., Newstein D., Guerci A.D. Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol. 36:2000;1253-1260.
20. Taylor A.J., Feuerstein I., Wong H., Barko W., Brazaitis M., O'Malley P.G. Do conventional risk factors predict subclinical coronary artery disease? Results from the Prospective Army Coronary Calcium Project. Am Heart J. 141:2001;463-468.
21. Greenland P., Abrams J., Aurigemma G.P., Bond M.G., Clark L.T., Criqui M.H., Crouse J.R. III, Friedman L., Fuster V., Herrington D.M., et al. AHA Conference Proceedings Prevention Conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention. Noninvasive tests of atherosclerotic burden. Circulation. 101:2000;111-116.
22. Hunziker P.R., Imsand C., Keller D., Hess N., Barbosa V., Nietlispach F., Liel-Cohen N., Weyman A.E., Pfisterer M., Buser P. Bedside quantification of atherosclerosis severity for cardiovascular risk stratification a prospective cohort study. J Am Coll Cardiol. 39:2002;702-709.
23. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., Deanfield J., Drexler H., Gerhard-Herman M., Herrington D., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 39:2002;257-265.
24. Schächinger V., Britten M.B., Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 101:2000;1899-1906.
25. Halcox J.P.J., Schenke W.H., Zalos G., Mincemoyer R., Prasad A., Waclawiw M.A., Nour K.R., Quyyumi A.A. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 106:2002;653-658.
26. Järvisalo M.J., Jartti L., Näntö-Salonen K., Irjala K., Rönnemaa T., Hartiala J.J., Celermajer D.S., Raitakari O.T. Increased aortic intima-media thickness a marker of preclinical atherosclerosis in high-risk children. Circulation. 104:2001;2943-2947.
27. Kim W.Y., Stuber M., Börnert P., Kissinger K.V., Manning W.J., Botnar R.M. Three-dimensional black-blood cardiac magnetic resonance coronary vessel wall imaging detects positive arterial remodeling in patients with nonsignificant coronary artery disease. Circulation. 106:2002;296-299.
28. Smith S.C. Jr, Greenland P., Grundy S.M. AHA Conference Proceedings Prevention Conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention. Executive summary. Circulation. 101:2000;111-116.
29. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
30. Schartl M., Bocksch W., Koschyk D.H., Voelker W., Karsch K.R., Kreuzer J., Hausmann D., Beckmann S., Gross M., German Atorvastatin Intravascular Ultrasound Study Investigators (GAIN). Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation. 104:2001;387-392.
31. Furberg C.D., Adams H.P. Jr, Applegate W.B., Byington R.P., Espeland M.A., Hartwell T., Hunninghake D.B., Lefkowitz D.S., Probstfield J., Riley W.A., Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 90:1994;1679-1687.
32. Mercuri M., Bond M.G., Sirtori C.R., Veglia F., Crepaldi G., Feruglio F.S., Descovich G., Ricci G., Rubba P., Mancini M., et al. Pravastatin reduces carotid intima-thickness progression in an asymptomatic hypercholesterolemic Mediterranean population the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med. 101:1996;627-634.
33. Hedblad B., Wikstrand J., Janzon L., Wedel H., Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation. 103:2001;1721-1726.
34. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J.P., Stalenhoef A.F.H. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP) a prospective, randomised, double-blind trial. Lancet. 357:2001;577-581.
35. Callister T.Q., Raggi P., Cooil B., Lippolis N.J., Russo D.J. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med. 339:1998;1972-1978.
36. Taylor A.J., Kent S.M., Flaherty P.J., Coyle L.C., Markwood T.T., Vernalis M.N. ARBITER Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 106:2002;2055-2060.
37. Raggi P., Callister T.Q., Davidson M., Welty F.K., Bachmann G.A., Laskey R., Pittman D., Kafonek S., Scott R. Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. Am Heart J. 141:2001;722-726.